Latest News and Press Releases

WALTHAM, Mass. and LONDON, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal...

WALTHAM, Mass. and LONDON, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal...

WALTHAM, Mass. and LONDON, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal...

WALTHAM, Mass. and LONDON, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal...

WALTHAM, Mass. and LONDON, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal...

NSR-RPGR data presented at EURETINA 2018 Congress demonstrated proof of concept with durable dose-related improvements seen as early as month 1 across multiple microperimetry analyses Preliminary...

WALTHAM, Mass. and LONDON, United Kingdom, Sept. 13, 2018 (GLOBE NEWSWIRE) --  Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare...

Regenerative Medicine Advanced Therapy (RMAT) Designation received in June 2018 for NSR-REP1 in Choroideremia Preliminary data from Phase 1/2 XIRIUS trial for X-Linked Retinitis Pigmentosa expected...

WALTHAM, Mass. and LONDON, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ: NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal...

First gene therapy RMAT designation for an inherited retinal diseaseSTAR Phase 3 registrational trial ongoing and FDA interactions plannedRMAT designation enables closer and more frequent...